Phosphodiesterase 11: A brief review of structure, expression and function

International Journal of Impotence Research

Volumn 18, Issue 6, 2006, Pages 501-509

  Makhlouf, A ^a   Kshirsagar, A ^a   Niederberger, C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Erectile dysfunction; Phosphodiesterase; Spermatogenesis; Tadalafil

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; BAY 607550; CILOMILAST; CILOSTAMIDE; DIPYRIDAMOLE; ISOBUTYLMETHYLXANTHINE; ISOENZYME; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 11; PHOSPHODIESTERASE INHIBITOR; ROFLUMILAST; ROLIPRAM; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; VINPOCETINE; ZAPRINAST; ZARDAVERINE;

CLINICAL TRIAL; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ISOLATION; ENZYME LOCALIZATION; ENZYME STRUCTURE; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; GENE STRUCTURE; HUMAN; IC 50; MALE FERTILITY; MALE INFERTILITY; MEDICAL LITERATURE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUBLICATION; REPRODUCTION; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; CLONING, MOLECULAR; GENE EXPRESSION PROFILING; HUMANS; PHOSPHORIC DIESTER HYDROLASES; REPRODUCTION;

EID: 33750484640     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901441     Document Type: Review

References (33)

1. Lin CS, Xin ZC, Lin G, Lue TF. Phosphodiesterases as therapeutic targets. Urology 2003; 61: 685-691.
2. Saenz de Tejada I, Angulo Frutos J, Gaudo M, Florio V. Comparative selectivity profiles of Tadalafil, Sildenafil and Vardenafil using an in vitro phosphodiesterase activity assay. Int J Impot Res 2002; 14(Suppl 4): S20-S32.
3. Gbekor E, Bethel S, Fawcett L, Mount N, Phillips S. Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families. Eur Urol Suppl 2002; 1(Suppl 1): 63.
4. Maw GN, Allerton CM, Gbekor E, Million WA. Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors. Bioorg Med Chem Lett 2003; 13: 1425-1428.
5. Weeks JL, Zoraghi R, Beasley A, Sekhar KR, Francis SH, Corbin JD. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 2005; 17: 5-9.
6. Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004; 16(Suppl 1): S11-S14.
7. Pyne NJ, Furman BL. Cyclic nucleotide phosphodiesterases in pancreatic islets. Diabetologia 2003; 46: 1179-1189.
8. Manallack DT, Hughes RA, Thompson PE. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem 2005; 48: 3449-3462.
9. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003; 64: 533-546.
10. Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, Omori K. Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J Biol Chem 2000; 275: 31469-31479.
11. Yuasa K, Ohgaru T, Asahina M, Omori K. Identification of rat cyclic nucleotide phosphodiesterase 11A (PDE11A): comparison of rat and human PDE11A splicing variants. Eur J Biochem 2001; 268: 4440-4448.
12. Hetman JM, Robas N, Baxendale R, Fidock M, Phillips SC, Soderling SH et al. Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci USA 2000; 97: 12891-12895.
13. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 2000; 97: 3702-3707.
14. Yuasa K, Kanoh Y, Okumura K, Omori K. Genomic organization of the human phosphodiesterase PDE11A gene. Evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem 2001; 268: 168-178.
15. Zoraghi R, Corbin JD, Francis SH. Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins. Mol Pharmacol 2004; 65: 267-278.
16. Baxendale RW, Fraser LR. Mammalian sperm phosphodiesterases and their involvement in receptor-mediated cell signaling important for capacitation. Mol Reprod Dev 2005; 71: 495-508.
17. Turko IV, Francis SH, Corbin JD. Binding of cGMP to both allosteric sites of cGMP-binding cGMPspecific phosphodiesterase (PDE5) is required for its phosphorylation. Biochem J 1998; 329: 505-510.
18. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 2003; 22: 469-478.
19. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D. Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 2003; 160: 719-727.
20. Pomara G, Morelli G. Re: Montorsi et al. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur urol 2005; 47: 612-621.
21. Loughney K, Taylor J, Florio VA. 3′,5′-cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int J Impot Res 2005; 17: 320-325.
22. D'Andrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, Lundeen S. Expression of PDE11A in normal and malignant human tissues. J Histochem Cytochem 2005; 53: 895-903.
23. Baxendale RW, Burslem F, Phillips SC. Phosphodiesterase type 11 (PDE11) cellular localization: progress towards defining a physiological role in testis and/or reproduction. J Urol 2001; 165(Suppl): 340.
24. Baxendale RW, Wayman CP, Turner L, Phillips SC. Cellular localization of phosphodiesterase type 11 (PDE11) in human corpus cavernosum and the contribution of PDE11 inhibition on the nerve stimulated relaxation. J Urol 2001; 165(Suppl): 340.
25. Wayman C, Phillips S, Lunny C, Webb T, Fawcett L, Baxendale R et al. Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int J Impot Res 2005; 17: 216-223.
26. Pomara G, Morelli G, Turchi P, Caglieresi C, MOschini C, Canale D et al. Effect of acute in vivo sildenafil or tadalafil treatments on semen parameters in patients with fertility problem, a randomized, double-blind, crossover study. J Sex Med 2004; 2(Suppl 2): 23 (PS-5-9).
27. Sinclair ML, Wang XY, Mattia M, Conti M, Buck J, Wolgemuth DJ et al. Specific expression of soluble adenylyl cyclase in male germ cells. Mol Reprod Dev 2000; 56: 6-11.
28. Nantel F, Monaco L, Foulkes NS, Masquilier D, LeMeur M, Henriksen K et al. Spermiogenesis deficiency and germ-cell apoptosis in CREM-mutant mice. Nature 1996; 380: 159-162.
29. de Lamirande E, Leclerc P, Gagnon C. Capacitation as a regulatory event that primes spermatozoa for the acrosome reaction and fertilization. Mol Hum Reprod 1997; 3: 175-194.
30. Kshirsagar A, Niederberger C. Are prostates and male infertility related? AUANEWS 2005; 10: 9-10.
31. Cialis® (Tadalafil) label insert. http://www.fda.gov/cder/foi/ label/2005/021368s006lbl.pdf, p 19.
32. Sausen PJ, Reams RY, Morford LL, Dietsch GN. Tadalafil has no effect on testes in rodents. Int J Impot Res 2002; 14(Suppl 4): S20-S32.
33. Hellstrom WJ, Overstreet JW, Yu A, Saikali K, Shen W, Beasley Jr CM et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003; 170: 887-891.